Zimulti
E874319
Zimulti is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
anti-obesity drug
ⓘ
brand name drug ⓘ |
| ATCCode | A08AX01 ⓘ |
| belongsTo | Sanofi obesity drug portfolio ⓘ |
| blackBoxConcern | suicidality risk ⓘ |
| chemicalName | rimonabant NERFINISHED ⓘ |
| contraindication |
major depression
ⓘ
ongoing psychiatric disorders ⓘ |
| developedBy | Sanofi-Aventis NERFINISHED ⓘ |
| developmentStatus | development terminated for commercial use ⓘ |
| drugClass | cannabinoid receptor antagonist ⓘ |
| firstApprovalRegion | European Union NERFINISHED ⓘ |
| firstApprovalYear | 2006 ⓘ |
| hasActiveIngredient | rimonabant ⓘ |
| hasAdverseEffect |
anxiety
ⓘ
depression ⓘ insomnia ⓘ mood disorders ⓘ nausea ⓘ suicidal ideation ⓘ vomiting ⓘ |
| indication |
obesity
ⓘ
smoking cessation (investigational) ⓘ weight management ⓘ |
| legalStatus | discontinued ⓘ |
| mechanismOfAction | selective CB1 receptor antagonism ⓘ |
| pharmacologicalClass | anorectic agent ⓘ |
| reasonForWithdrawal |
increased risk of depression
ⓘ
increased risk of suicidal behavior ⓘ psychiatric side effects ⓘ |
| receptorBinding | CB1 receptor antagonist ⓘ |
| regulatoryStatus |
not approved by FDA in United States
ⓘ
withdrawn from market in European Union ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | CB1 receptor NERFINISHED ⓘ |
| therapeuticArea | metabolic disorders ⓘ |
| therapeuticEffect |
reduction of appetite
ⓘ
weight loss ⓘ |
| tradeNameOf | rimonabant NERFINISHED ⓘ |
| withdrawalYear | 2008 ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.